• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Alternative treatment for acute promyelocytic leukemia promising

bys25qthea
July 11, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Patients with newly-diagnosed low-to-intermediate risk acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) plus arsenic trioxide experienced similar outcomes to patients treated with conventional ATRA plus anthracycline-based chemotherapy. 

2. Patients with APL treated with ATRA plus arsenic trioxide experienced significantly lower rates of hematologic side effects (neutropenia, thrombocytopenia, fever of unknown origin, infectious episodes) but significantly higher rates of hepatic toxic effects and prolongation of the QTc interval. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: This randomized control study showed that in newly diagnosed patients with low-to-intermediate risk APL, combination induction and consolidation therapy with ATRA and arsenic trioxide was non-inferior to the current standard-of-care treatment with ATRA-anthracycline chemotherapy. Benefits of combination therapy with arsenic trioxide were measured in terms of event-free survival at 2 years after diagnosis and appear to derive from reduced incidence of severe cytopenias, mucositis, and infections, which were more commonly associated with chemotherapy.  However, these benefits were counterbalanced by a significantly increased rate of toxic hepatic effects and prolonged QTc intervals in patients treated with ATRA-arsenic trioxide, warranting close monitoring of serum electrolytes, liver transaminases, and cardiac arrhythmias. The median follow-up period of 34.4 months suggests that future studies, potentially with larger treatment groups, will be required to investigate the longer term usage of this drug combination.

Click to read the study, published today in NEJM

Relevant Reading: Management of acute promyelocytic leukemia

RELATED REPORTS

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

Unsweetened coffee consumption is associated with reduced risk of mortality

In-Depth [randomized control trial]: This study compared the efficacy and adverse effect profiles of ATRA-arsenic trioxide versus standard-of-care ATRA-chemotherapy for the treatment of newly diagnosed APL classified as low-to-intermediate risk (WBC count at diagnosis ≤ 10×109 per liter).  162 patients were randomized into either treatment arm from multiple centers across three countries.

The primary end point was event-free survival at 2 years after diagnosis, with treatment failure defined as lack of complete hematologic or molecular remission after induction therapy or three consolidation courses respectively, molecular relapse, hematologic collapse, or death. The median follow-up period was 34.4 months.

97% of patients in the ATRA-arsenic trioxide group were alive and event-free at 2 years as compared with 86% in the ATRA-chemotherapy group (95% CI 2 to 22 percentage points, P<0.001 for noninferiority and P=0.02 for superiority).  Severe neutropenia and severe thrombocytopenia lasting more than 15 days were significantly more frequent in the ATRA-chemotherapy group than the ATRA-arsenic trioxide group. There were 59 episodes of fever of unknown origin and infections in the ATRA-chemotherapy group versus 26 episodes in the ATRA-chemotherapy group (P<0.001). However, 63% of patients in the ATRA-arsenic trioxide group versus 6% in the ATRA-chemotherapy group experienced severe hepatic toxicity (P<0.001).

By Matthew Growdon and Mitalee Patil

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

 

Tags: acute promyelocytic leukemiacancerhealthleukemia
Previous Post

Pneumococcal vaccine associated with a decrease in pneumonia hospitalizations

Next Post

The PIVOT trial: Radical prostatectomy versus observation [Classics Series]

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

June 30, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

June 29, 2022
European data showed coffee consumption associated with lower mortality
Cardiology

Unsweetened coffee consumption is associated with reduced risk of mortality

June 21, 2022
#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia
StudyGraphics

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

June 12, 2022
Next Post

The PIVOT trial: Radical prostatectomy versus observation [Classics Series]

Gestational weight loss may improve outcomes for obese women

African Americans, obese overrepresented in young heart failure cases

Everolimus only protects against early cardiac allograft vasculopathy

Antibiotic implants reduce surgical site infections

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Remdesivir does not reduce mortality in ventilated patients with COVID-19
  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.